SCO-267
Modify Date: 2024-01-11 09:57:54
SCO-267 structure
|
Common Name | SCO-267 | ||
|---|---|---|---|---|
| CAS Number | 1656261-09-4 | Molecular Weight | 614.77 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C36H46N4O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SCO-267SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes[1]. |
| Name | SCO-267 |
|---|
| Description | SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes[1]. |
|---|---|
| Related Catalog | |
| Target |
GPR40[1] |
| In Vitro | SCO-267 (CHO cells) activates the Gαq, Gαs, and Gα12/13 pathways and β-Arrestin Recruitment. SCO-267 is allosteric with fasiglifam and an endogenous ligand[1]. |
| In Vivo | SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect[1]. Animal Model: N-STZ rats[1] Dosage: 1 or 10 mg/kg Administration: P.o.; Result: Improved insulin sensitivity and exerted sustained glucose-lowering effect. |
| References |
| Molecular Formula | C36H46N4O5 |
|---|---|
| Molecular Weight | 614.77 |